RLAY(RLAY)
RLAY
ANALYST COVERAGE15 analysts
BUY
▲ +81.8%upside to target
L $18.00
Med $22.00consensus
H $25.00PRICE
Prev Close
12.20
Open
12.23
Day Range11.63 – 12.57
11.63
12.57
52W Range2.75 – 17.32
2.75
17.32
64% of range
VOLUME & SIZE
Avg Volume
3.0M
FUNDAMENTALS
P/E Ratio
-7.8x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.92
High vol
TECHNICAL
RSI (14)
46
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 20
DEx-Dividend
In 90 days
Aug 17
PDividend Pay
In 104 days
Aug 31
Key MetricsTTM
Market Cap$2.32B
Revenue TTM$10.68M
Net Income TTM-$272.70M
Free Cash Flow-$213.38M
Gross Margin89.7%
Operating Margin-2776.6%
Net Margin-2554.1%
Return on Equity-43.9%
Return on Assets-39.0%
Debt / Equity0.05
Current Ratio22.13
EPS TTM$-1.52
RLAY News
About
Relay Therapeutics, Inc. operates as a biotechnology company. The Company develops durgs for the treatment of cancer. Relay Therapeutics serves customers in the United States.
Sector
Industry
Biological Product (except Diagnostic) Manufacturing
Website
David Elliot ShawFounder
Matthew JacobsonFounder
Dorothee KernFounder
Jim WattersChief Scientific Officer
Peter RahmerChief Corporate Development Officer
Thomas CatinazzoChief Financial Officer
Imogen PryceChief Operating Officer of R&D
Soo-Yeun LimSenior Vice President & General Counsel
Donald A. BergstromPresident of Research & Development
Mahesh PadvalChief Pharmaceutical Development Officer
Mark MurckoFounder & Independent Director
Sanjiv K. Patel MBBSChief Executive Officer, President & Director
Brenton MarSenior Vice President of Clinical Development